- Home
- Collaborations
Collaborations
Our Collaborations
shenzhen Pregene Biopharma and CellPoint have signed an exclusive licence agreement to develop and commercialise the former’s cell therapy, PRG-1801, to treat haematological indications in the US and Europe. shenzhen Pregene Biopharma and CellPoint have signed an exclusive licence agreement to develop and commercialise the former’s cell therapy, PRG-1801, to treat haematological indications in the US and Europe.